Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04633304
Other study ID # STP-001
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 15, 2020
Est. completion date December 31, 2023

Study information

Verified date February 2023
Source California Institute of Renal Research
Contact Osman Khawar, MD
Phone 7602943162
Email okhawar@bnmg.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an investigator-initiated post-marketing study that will evaluate use of the WaveLinQ system, a new and novel method of fistula creation using a percutaneous method in patients who require the creation of an arteriovenous fistula (AVF).


Description:

This investigator-initiated post-marketing study will evaluate use of the WaveLinQ system, a new and novel method of fistula creation, which uses a percutaneous method to create an AVF. Thirty male and female subjects with CKD 3-5 and who are clinical indicated for arteriovenous fistula (AVF) creation will be enrolled using the WaveLinQ device. Eligibility confirmation will be confirmed during screening up to 28 days from the index procedure. Subjects who are eligible will undergo fistula creation per standard institutional technique (index/baseline) and be followed at least monthly for 6 months per their standard of care plan. Primary, clinical and functional patency will be observed throughout the trial in addition to other data collection points per protocol. The expected total duration of subject participation from screening until the end of study is up to 7 months.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date December 31, 2023
Est. primary completion date December 15, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Male or Female Age of at least 18 years 2. CKD 3 through 5 as measured by GFR 45 and under by MDRD equation on two separate occasions at least 3 months apart. 3. Provide written informed consent using a form that is approved by the Institutional Review Board (IRB) prior to collection of study data or performance of study procedures. 4. Currently not on hemodialysis. 5. Life expectancy of at least one year 6. Meets Anatomical Criteria for EndoAVF creation via pre-procedure Duplex or Venography Vascular anatomy suitable for creation of the AV fistula 7. Willing to comply with the specified follow-up evaluations Exclusion Criteria: 1. Anatomical exclusion criteria met 2. Thought to need dialysis within 30 days. 3. The subject is in a hypercoagulable state. 4. The subject has known bleeding diathesis. 5. The subject has insufficient cardiac output to support a native fistula in the opinion of the investigator. 6. Known history of active intravenous drug abuse. 7. The subject has a known allergy or hypersensitivity to contrast media which cannot be adequately pre-medicated. 8. The subject has known adverse effects to sedation and/or anesthesia which cannot be adequately pre-medicated. 9. Evidence of active infection on the day of the index procedure (temperature of = 38.0° Celsius and/ or WBC of = 12,000 cells/ µL, if collected).

Study Design


Related Conditions & MeSH terms


Intervention

Device:
EndoAVF System for endovascular AV fistula creation
AV fistula creation

Locations

Country Name City State
United States California Institute of Renal Research Escondido California

Sponsors (1)

Lead Sponsor Collaborator
California Institute of Renal Research

Country where clinical trial is conducted

United States, 

References & Publications (6)

Berland TL, Clement J, Griffin J, Westin GG, Ebner A. Endovascular Creation of Arteriovenous Fistulae for Hemodialysis Access with a 4 Fr Device: Clinical Experience from the EASE Study. Ann Vasc Surg. 2019 Oct;60:182-192. doi: 10.1016/j.avsg.2019.02.023. — View Citation

Inston N, Khawaja A, Tullett K, Jones R. WavelinQ created arteriovenous fistulas versus surgical radiocephalic arteriovenous fistulas? A single-centre observational study. J Vasc Access. 2020 Sep;21(5):646-651. doi: 10.1177/1129729819897168. Epub 2020 Jan 2. — View Citation

Jones RG, Khawaja A, Tullett K, Inston NG. Early experience and observations in endovascular dialysis fistula re-intervention. J Vasc Access. 2020 Nov;21(6):818-825. doi: 10.1177/1129729819888374. Epub 2019 Dec 9. — View Citation

Lok CE, Rajan DK, Clement J, Kiaii M, Sidhu R, Thomson K, Buldo G, Dipchand C, Moist L, Sasal J; NEAT Investigators. Endovascular Proximal Forearm Arteriovenous Fistula for Hemodialysis Access: Results of the Prospective, Multicenter Novel Endovascular Ac — View Citation

Radosa CG, Radosa JC, Weiss N, Schmidt C, Werth S, Hofmockel T, Plodeck V, Gatzweiler C, Laniado M, Hoffmann RT. Endovascular Creation of an Arteriovenous Fistula (endoAVF) for Hemodialysis Access: First Results. Cardiovasc Intervent Radiol. 2017 Oct;40(1 — View Citation

Zemela MS, Minami HR, Alvarez AC, Smeds MR. Real-World Usage of the WavelinQ EndoAVF System. Ann Vasc Surg. 2021 Jan;70:116-122. doi: 10.1016/j.avsg.2020.05.006. Epub 2020 May 15. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Procedure Success Successful endoAVF creation confirmed by intraprocedural angiography or duplex Ultrasound post procedure Interval of time from access placement until any intervention is undertaken to maintain or re-establish patency - 6 weeks
Secondary Physiologically mature endoAVF at 6 months Percent of patients who did not require any intervention to be undertaken to maintain or re-establish patency 6 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03596749 - The Effect of Sevelamer Carbonate on Serum Trimethylamine-n-Oxide (TMAO) Level in Patients With Chronic Kidney Disease (CKD) Stage 3b-4 Phase 3
Not yet recruiting NCT05514184 - Plant-Focused Nutrition in Patients With Diabetes and Chronic Kidney Disease N/A
Recruiting NCT03415074 - Could Ketoanalogue-supplemented Low Protein Diet Defer Dialysis in Advanced Diabetic Kidney Disease? (K-DDD) N/A
Not yet recruiting NCT04102319 - Serum Hepcidin, Haemoglobin Level and Iron Status in Chronic Kidney Disease Patients (CKD) With Anaemia
Recruiting NCT05309785 - Safety and Efficacy of Canagliflozin in Advanced CKD Phase 4
Not yet recruiting NCT06094920 - Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial Phase 4
Completed NCT05705011 - Frailty, Cognitive Function and Health-related Quality of Life in Older Adults With Advanced Chronic Kidney Disease.
Completed NCT03588884 - Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency Phase 4
Enrolling by invitation NCT06083545 - The Effects of Application Intervention on the Physiological Indicators and Low Protein Diet Cognition Among the Patients With Chronic Kidney Disease N/A
Recruiting NCT05508009 - Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor Phase 1/Phase 2
Completed NCT04862715 - The Iron and Muscle Study Phase 4